323 related articles for article (PubMed ID: 32250517)
1. A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy.
Liu Y; Hu X; Jiang J; Yang L; Zhou S; Liu P; Li J; Wang Y; Hao X; Shi Y
Oncologist; 2020 May; 25(5):e833-e842. PubMed ID: 32250517
[TBL] [Abstract][Full Text] [Related]
2. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Geng N; Ding CM; Liu ZK; Song S; Hu WX
Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer.
Luo H; Zhang L; Yang B; Feng Y; Xiong Y; Zhang S; Li X; Qian C; Dong W; Dai N
Invest New Drugs; 2020 Feb; 38(1):148-159. PubMed ID: 31399906
[TBL] [Abstract][Full Text] [Related]
5. Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study.
Xu Y; Huang Z; Lu H; Yu X; Li Y; Li W; Chen J; Chen M; Gong L; Chen K; Qin J; Xu X; Jin Y; Zhao J; Shi X; Han N; Xie F; Zhang P; Xu W; Fan Y
Br J Cancer; 2019 Oct; 121(8):640-646. PubMed ID: 31523058
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.
Liu Q; Xu JY; Xu YH; Chen M; Deng LC; Wu JP; Zhou T; Zhang LQ; Tan J; Pu XX; Shang YL; Hua J; Li YQ; Cai W; Gu YL; Peng XC; Chan PC; Jabbour SK; Nam HS; Hua D
Transl Lung Cancer Res; 2022 May; 11(5):832-844. PubMed ID: 35693282
[TBL] [Abstract][Full Text] [Related]
7. Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study.
Li H; Zeng J; Jin X; Yu X; Zhou G; Hong W
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1083-1090. PubMed ID: 30937519
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
[TBL] [Abstract][Full Text] [Related]
10. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.
Yan X; Wang Q; Wang H; Li P; Zhang G; Zhang M; Zheng X; Yang J; Zhang X; Ma Z
J Cancer Res Clin Oncol; 2019 Jan; 145(1):235-240. PubMed ID: 30293117
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second-line treatment in advanced small cell lung cancer.
Xu Y; Wang X; Sun C; Gao Z; He H; Qiu S; Guo Y; Ma X; Song J; Ma K
Cancer Med; 2023 Feb; 12(3):2979-2989. PubMed ID: 36082491
[TBL] [Abstract][Full Text] [Related]
12. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
[No Abstract] [Full Text] [Related]
13. Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review.
Liu YY; Chen T; Shen D; Zhang WY; Wang CG; Jiang JH; Zeng DX
J Int Med Res; 2020 Mar; 48(3):300060519887276. PubMed ID: 31847652
[TBL] [Abstract][Full Text] [Related]
14. Apatinib as maintenance therapy following standard first-line chemotherapy in extensive disease small cell lung cancer: A phase II single-arm trial.
Teng F; Xing P; Yang K; Gao L; Tian Z; Li J
Thorac Cancer; 2022 Feb; 13(4):557-562. PubMed ID: 35029038
[TBL] [Abstract][Full Text] [Related]
15. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
16. Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial.
He Z; Zhou H; Wang J; Li D; Zhang X; Wang P; Ma T; Zhang Y; Tian C; Chen Y; Zou M; Han Y; Xu C; Ma S; Wang L; Wu X; Chen G; Wang Q
Transl Lung Cancer Res; 2021 Feb; 10(2):889-899. PubMed ID: 33718030
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.
Zhang X; Xiong Y; Xia Q; Wu F; Liu L; Zhou Y; Zeng L; Zhou C; Xia C; Jiang W; Liao D; Xiao L; Liu L; Yang H; Guan R; Li K; Wang J; Lei G; Zhang Y; Yang N
JAMA Netw Open; 2020 Mar; 3(3):e201226. PubMed ID: 32191330
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
[TBL] [Abstract][Full Text] [Related]
20. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
